Clinical trial
An Open-label, Parallel Group, Randomized, Two-sequence, Three-way Crossover Study to Assess the Relative Bioavailability of Solifenacin Succinate and Mirabegron Fixed-dose Combination Tablets Compared to Co-administration of Single Entity Tablets at Three Dose Strengths in Healthy Male and Female Subjects
NCT02010944 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Parallel Group, Randomized, Two-sequence, Three-way Crossover Study to Assess the Relative Bioavailability of Solifenacin Succinate and Mirabegron Fixed-dose Combination Tablets Compared to Co-administration of Single Entity Tablets at Three Dose Strengths in Healthy Male and Female Subjects
- Lead sponsor
- Astellas Pharma Europe B.V.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 30, 2012
- Completion date
- November 30, 2012
- Enrollment
- 72 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
bioavailability, healthy subjects, phase 1